• Pharmaceutical services business Trxade Group Inc. continues to build on a decade’s experience in sustaining independent health care providers by expanding its revenue base and number of subscribers to its business-to-business platform
• The company recently reported year-over-year revenue growth of 173 percent for its third quarter
• Trxade Group’s financial growth is largely due to income from its acquisition of Community Specialty Pharmacy, LLC last year, and the company continues to expand its medical service opportunities and revenue base with a new online consultation feature
• The online consultation service will establish “health hubs” through independent pharmacies so underserved patients can consult face-to-face with board-certified medical providers in a secure environment and then access needed prescriptions
• Trxade Group will present its accomplishments at this month’s LD Micro Main Event in Los Angeles, where members of the investment community focused on the microcap space will gather December 10-12
• The LD Micro Main Event will be attended by more than 1,400 individuals with presentations by 275 businesses

Business-to-business pharmacy services supplier Trxade Group Inc. (OTCQB: TRXD), a health care industry influencer passionate about sustaining independent, community-based drug store operations, will round out a year of continued expansion by presenting its corporate operations to attendees at this year’s LD Micro Main Event microcap financing opportunity.

The LD Micro Main Event is an influential gathering of the investment community focused on the microcap space. This year’s 12th annual event will take place in Los Angeles on Dec. 10-12 and will be attended by more than 1,400 individuals. Trxade Group will present during the event’s opening day, helping to get the ball rolling at 9:40 a.m. local time.

“This year’s Main Event is our largest event to date, with 275 companies set to present and meet with investors,” LD Micro President Chris Lahiji stated in a news release announcing Trxade’s appearance (http://ibn.fm/YC42f). “Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the more interesting businesses in the world to our ever-growing community. Investor interest in our events has also never been stronger, and that goes for our commitment to philanthropy as well.”

Trxade Group is developing its growing platform of integrated drug procurement, delivery and health care services that enables independent pharmacies as well as product sellers to competitively strengthen their business profiles through price transparency and increased profit margins for their own pharmaceuticals, accessories and services.

The company recently announced record revenues that marked a 173 percent increase in year-over-year third quarter sales, driven largely by Trxade Group’s acquisition of Community Specialty Pharmacy, LLC last year. Community Specialty Pharmacy’s Florida-based business-to-consumer operation includes online access certified independently with 15 state licenses (http://ibn.fm/CDCLd).

The company’s network of subscribers on its supplier-to-pharmacy trading platform also had grown by 431 new independent pharmacies by the end of the quarter, showing a 54 percent increase from a year earlier.

Trxade Group further augmented its members’ health care capacities by finalizing an agreement in November between its subsidiary Bonum Health and Benzer Pharmacy, a chain of independent retail pharmacies in Florida, to launch the ‘Bonum Health Hub’ initiative. The health hub will include a secure virtual examination room through which 800 board-certified medical providers and patients can use face-to-face consultation methods via a protected online portal to address health care concerns (http://ibn.fm/8hewO).

The health hub will launch during the next three months and will extend the reach of independent pharmacies in both rural and urban communities where traditional medical services may not be close at hand or where some members of the community may not be able to afford those services, especially if they lack insurance coverage.

The Bonum Health Hub will provide the technology and capabilities for patients to fill prescriptions within the same pharmacy where the health hub is located. The initial pilot will take place at Benzer locations, then expand throughout Trxade Group’s network of thousands of registered pharmacies nationwide. CEO Suren Ajjarapu stated there are plans to have 100 Benzer Pharmacy locations providing collaborative care by the end of 2020 and then for the model to continue to expand throughout the company’s network.

“This new milestone will not only encourage patients to take medical care into their own hands but will also allow uninsured patients to get the help they need for an affordable price, and from the convenience of a community pharmacy,” Benzer Pharmacy President Alpesh Patel stated in a news release announcing the agreement (http://ibn.fm/c9Sep).

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at  http://ibn.fm/TRXD

• LiveWire collaborates with Basso Botanicals to launch new cannabis, cannabis/CBD dosage and verification system
• LVVV system improves transparency of cannabis industry by giving consumers, business, municipalities ability to verify product standards
• System makes it easier for growers, manufacturers and retailers to comply with increasingly strict industry requirements

LiveWire Ergogenics Inc. (OTC: LVVV), a health and wellness company that has taken unique and bold steps forward in the cannabis industry, recently announced the launch of a cannabis testing and verification system that can be used to verify potency, materials of origin, dosages and more. The system is called the 7X Pure Compliance and Dosage Verification System (http://ibn.fm/Bp0GD). In launching the new system, LiveWire partnered with Basso Botanicals, an experienced company that has been devoted for years to provide CBD and cannabis products of the highest quality.

The 7X Pure Verification System was first used to put Basso Botanicals’ 725 mg Peppermint Tincture to the test (http://ibn.fm/WcW4B). This 15ml bottle passed the stringent testing of LiveWire’s new system, making it the first 7X Pure product to hit the California cannabis/CBD market. In a news release, LiveWire CEO Bill Hodson said that the company is “pleased that Basso’s Peppermint Tincture will be the first product being marketed nationwide after having passed through the rigorous 7X Pure verification system.”

Basso Botanicals plans to use LVVV’s 7X Pure Verification System to vet all of its products so that the company can deliver fully transparent, precise, high-quality CBD and cannabis product analysis to its customers. Basso Botanicals plans to complete this process within the year. The next Basso Botanicals 7X Pure product, a 150 mg topical, is set to launch in January 2020.

LiveWire is “looking forward to making the 7X Pure system available to manufacturers in the entire industry, creating the opportunity to increase transparency and accountability throughout the supply chain with the goal to improve product quality and reliability and increase consumer confidence in their product purchase decisions,” according to Hodson.

The 7X Pure Verification System also makes it easier for those that grow and manufacture cannabis and CBD products to meet evolving compliance requirements. On top of this, the system provides increased assurance to all those involved in the cannabis industry, including municipalities, by simply scanning the product’s QR code, which takes the user to a website in order to verify the detailed product claims and test results and display the verification certificate.

Manufacturers that want to comply with the 7X Pure verification standard will need to submit documentation as well as a sample of their cannabis or CBD products. This information will be stored in an electronic database and then vetted to make sure that the 7X Pure standards have been met. Once products meet all 7X Pure standards, a verification certificate is issued. A QR code will then be placed on products, which consumers, businesses and others can scan with their mobile phones to access pertinent product data and confirm products are 7X Pure verified. Throughout the process, LiveWire will ensure that the intellectual property of the growers and manufacturers remains fully confidential.

Dale Hall, founder and CEO of Basso Botanicals, is pleased with the recent partnership formed with LiveWire as both companies work toward establishing and administering the new 7X system. He noted that Basso Botanicals has contributed its wealth of experience in the cannabis and CBD markets to help make “7X Pure the gold standard in the industry for the benefit of all cannabis customers.”

LiveWire Ergogenics specializes in identifying and monetizing current and future trends in the health and wellness industry. The company is focused on acquiring, managing and licensing specialized closed-loop, turnkey, cannabis, real-estate locations of fully compliant and permitted turnkey facilities to produce cannabis-based products and services in California and the statewide distribution of these products.

For more information, visit the company’s website at www.LiveWireErgogenics.com

NOTE TO INVESTORS: The latest news and updates relating to LVVV are available in the company’s newsroom at http://ibn.fm/LVVV

• CIIX CEO Warren Wang and CBD Biotech executives attended 2019 China Industrial Cannabis CBD Industry International Conference
• At well over one billion people, China’s cannabis industry market potential is four times the size of America’s
• CEO responds to stock’s fluctuating volatility, urges shareholders to continue to invest

ChineseInvestors.com Inc. (OTCQB: CIIX) is a leading purveyor of financial information and education for Chinese-speaking investors in the United States and China providing real-time market commentary, analysis, and educational-related services in Chinese character language sets. The products and services offered help investors make informed decisions and meet individualized financial goals. After creating inroads into the lucrative cannabis sector in the United States through its subsidiary CBD Biotech Inc., CIIX is leveraging its own financial expertise to establish itself as a leader in China’s emerging CBD industry.

On November 23-24, CBD Biotech executives attended the 2019 China Industrial Cannabis CBD Industry International Conference in Haerbing, China. Warren Wang, CEO of CIIX, joined Donald Baillargeon on MoneyTV to share highlights from the conference and recent company news.

Wang described the conference’s focus on the hemp/CBD industry in China, which cemented his belief that the industry has a bright future. China’s cannabis industry is in the early stage of development and has a large potential for growth. Institutional investors, analysts, and fund managers who are interested in the opportunities both in China and offshore were in attendance. Legalizations is slow in China, but the laws are changing, and investors are looking for potential opportunities. With approximately 1.4 billion people, China has four times the market potential of America. In a Wall Street Journal video, titled ‘Why China is Betting Big on CBD’ (http://ibn.fm/UwOFI), the consensus among Chinese entrepreneurs is that while the U.S. is a currently a major player, the future of the cannabis industry belongs to China.

CBD Biotech executives were on hand at November’s conference to feature new products and provide information and education on current products. The company is one of the first to enter this market and has laid the foundation for success as the hemp/CBD industry continues to grow in China (http://ibn.fm/2RjQj).

In the MoneyTV interview with Baillargeon, Wang also responded to CIIX stock’s fluctuating volatility, speaking to the company’s strong management team and focused achievement of long-term objectives. He reminded shareholders of Amazon’s early days where the value of stocks would fluctuate dramatically. Since CIIX is still a young company and has a promising future, Wang commented that “short term stock volatility is not going to effect the long-term picture.” For now, he encourages those who believe in CIIX to invest disposable money.

The strength of CIIX lies in its management team, long-term goals and strategy, and placement in a potentially explosive market.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• SRAX BIGtoken proprietary platform based on consumers’ rights to privacy, ownership of digital data
• BIGtoken platform allows consumers to own and earn from their digital data
• SRAX offers access to valuable proprietary data from consumers who opt in

SRAX Inc.’s (NASDAQ: SRAX) philosophy about the importance of consumers controlling and owning their own personal digital data has been reinforced by a YouTube video from Apple that tells consumers that their own private information on an iPhone – from personal health to text messages – should remain private. SRAX, a technology firm that permits consumers to control their own digital privacy data, is trending ahead of the curve in that respect. The company has been focused on empowering consumers to take control of their data since its inception.

The video explains to consumers that the information they have on their iPhone should remain private and that private and personal things “should belong to you.” The video (http://ibn.fm/e5ZHI) further notes that “there is more private information on your phone than in your home…. so many details about your life are right in your pocket. This makes privacy more important now than ever. Your location, your messages, your heart rate after a run. These are private things, personal things, and they should belong to you. Simple as that.”

SRAX’s philosophy is completely in line with Apple’s message about the importance of securing digital data. With consumer privacy in mind, SRAX developed its own platform, called BIGtoken, that asks consumers to voluntarily opt-in to participate (http://ibn.fm/SVKcP). BIGtoken is described by SRAX as “a platform to own and earn from your data,” adding that “your digital data is an extension of who you are, and it’s time to take back what is rightfully yours.” By securing consumers’ trust, SRAX is in the process of building the most valuable opted-in data set in the world.

What is unique about SRAX is that it offers consumers a secure and transparent environment to control their own privacy while also unlocking the value of their data. Taking care of the issue of consent immediately, SRAX asks users for permission to share data when they originally sign up for the BIGtoken platform.

The company’s proprietary technology then unlocks data to reveal a brand’s core consumers and the characteristics of those consumers across marketing channels. SRAX’s machine-learning technology analyzes marketing data, and its BIGtoken platform enables consumers to own, manage and sell access to their digital identity and data. Mutually beneficial, both consumer and marketing brands reap the rewards of data, and consumers are never blindsided by unforeseen privacy leaks. Additionally, this approach gives SRAX valuable proprietary data and multiple revenue streams, the company said in its SEC 10-Q filing in August 2019 (http://ibn.fm/YimIp).

“BIG token is a secure platform that empowers you to realize and claim the value of your digital self,” the website explains. “You have a right to privacy, awareness and choice when it comes to the data that you put out into the digital world. With BIG, you can own and earn from that data while staying connected to your community.”

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Two trends for 2019 – adjusting to changing customer behaviors and utilizing an independent sales force – have created unique opportunities from which Sharing Services has been perfectly positioned to benefit
• SHRG well-positioned in direct-selling industry thanks to its subsidiaries – Elevacity Global LLC and Elepreneurs LLC – which provide ideal avenues to make the most of top trends
• Elepreneurs created to answer the call for a new era of entrepreneurs

Sharing Services Global Corporation (OTCQB: SHRG), a diversified holding company that owns, operates or controls an interest in a variety of companies specializing in the direct-selling industry, is capitalizing on two trends that have had a tremendous impact in the direct-selling space this year.

Direct Selling News, the only publication dedicated to serving direct selling and network marketing executives in North America, just released an insightful article titled ‘5 Events That Impacted Direct Selling in 2019’ (http://ibn.fm/qQ6es). Two of the events – customer behaviors changing rapidly and partnering with an independent sales force to focus on customer acquisition – have created unique opportunities from which SHRG – with its longstanding emphasis on consumer health and wellness – has been ideally positioned to benefit.

“The most fundamental changes that are happening right now are centered on the consumer,” the article states. “With the rise of mobile, social and cloud technologies, customer expectations are increasing dramatically, and they are demanding a more seamless experience. They want to buy products where, when and how they want.”

In December 2017, SHRG launched two subsidiaries: Elevacity Global LLC and Elepreneurs LLC, both of which were created with the modern consumer in mind. These entities have provided ideal avenues for Sharing Services to make the most of these two key trends.

Elevacity Global is responsible for the manufacturing and distribution of products that are formulated to give consumers exactly what they want. Exclusive Elevacity products focus on creating health, wealth, and happiness through powerful nutritional products that contain ingredients that have been scientifically proven to stimulate the happiness hormones dopamine, oxytocin, serotonin and endorphins. The Elevacity brand of products includes nutritional and skin-care offerings that have been carefully selected to elevate the lives of SHRG consumers.

In addition to being nimble and dynamic in its approach to meeting consumers’ needs, Sharing Services is focused on partnering with its independent sales force in customer acquisition. The Direct Selling News article quoted guest author Wayne Moorehead, who noted that “there is a huge opportunity for us to partner more closely with our distributors, to be more involved in telling the brand story and in customer acquisition. I predict the brands that are able to bring together the best of direct selling with the best of direct to consumer are the ones who will be the most relevant five years from now. . . . We need to make learning about interacting with us more convenient, seamless and simple. We can no longer expect our customers, prospective customers or distributors to put up with outdated designs, clunky processes and outdated technologies.”

SHRG’s Elepreneurs is leveraging this timely opportunity. The subsidiary was created to answer the call for a new era of entrepreneurs, which SHRG calls Elepreneurs, who want to share superior, scientifically backed products in contemporary ways that fully utilize the new era of social media and a widening consumer base that crosses industries and borders. The company focuses on relationship marketing, which breaks the traditional direct-selling mold, creating big opportunities for small businesses across the company’s platform.

Sharing Services and its subsidiaries are perfectly positioned in a growing global direct-selling market. SHRG empowers entrepreneurs, building leadership skills and offering competitive products and services. The company’s business model is designed to elevate its Elepreneurs and reach its customer base with relationship marketing and social-media engagement.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• SPRWF launches Pūr Dew, an exclusive, full-spectrum CBD oil available under company’s wellness-focused brand, Blissco
• New product part of company’s strategic entry into one of the fastest-growing product segments
• Initially available in British Columbia, new product expected in other provinces in coming months

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), a global diversified portfolio of cannabis companies, has launched its newest product – Pūr Dew, an exclusive, full-spectrum CBD oil available under the company’s wellness-focused brand, Blissco (http://ibn.fm/8DYnc). The product marks a milestone for Supreme Cannabis Company as it enters the CBD market; current SPRWF products include dry flower from SPRWF subsidiary 7ACRES and high-THC cannabis oil from Khalifa Kush Enterprises Canada.

“We are excited to expand our product offering to include CBD, arguably one of the fastest-growing product segments on the market,” Supreme Cannabis Company CEO Navdeep Dhaliwal stated in a news release. “As Blissco’s first CBD oil, Pūr Dew offers consumers full-spectrum CBD and USDA-certified-organic MCT coconut oil. Our team worked incredibly hard to provide consumers with a product that retains the benefits of the plant and the natural terpenes. Pūr Dew can be taken directly or mixes well into beverages, such as smoothies. We are excited for consumers to try Pūr Dew.”

Made from pure-CBD cannabis oil and USDA-certified-organic MCT coconut oil, Pūr Dew is manufactured at the company’s facility in Langley, British Columbia. Through careful formulation and extraction, Blissco has retained delicate terpenes, giving the new CBD-oil product a gentle smell of clove, citrus and pine. Available initially in British Columbia, Pūr Dew will be available in other Canadian provinces throughout the next year.

In addition to prioritizing quality and creating a high-end product formulation, Supreme Cannabis and the Blissco brand have made sustainability a priority as well. Blissco sources packaging that is as environmentally friendly as possible. With that in mind, Pūr Dew comes in recyclable glass bottles with its outer cardboard packaging made from 100% post-consumer wastepaper.

Since 2014, Supreme Cannabis Company has emerged as one of the world’s fastest-growing, premium plant-driven lifestyle companies by effectively deploying capital, with an emphasis on disciplined growth and high-quality products. Noting that the CBD market for legal cannabis sales in Canada alone is expected to reach $4.7 billion by 2023, with sales in the United States projected to top $24 billion by that time (http://ibn.fm/99AHO), the company is strategically entering a lucrative market with a high-quality product offering.

Supreme Cannabis Company’s portfolio includes 7ACRES, its wholly owned subsidiary and multi-award-winning brand; Blissco, a wellness cannabis brand and a multi-licensed processor and distributor based in British Columbia; Truverra Inc., a global medicinal cannabis brand and licensed cultivator; Cambium Plant Sciences, a plant genetics and cultivation IP company; Medigrow Lesotho, a cannabis oil producer located in Southern Africa; Supreme Heights, an investment platform focused on CBD brands in the United Kingdom and Europe; and a brand partnership and licensing deal with Khalifa Kush Enterprises Canada.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• SHRG’s Elepreneurs subsidiary uses platform from Verb Technology for launch in United States; Canadian unveil to follow
• Five-star interactive sales marketing tool designed to help Elepreneurs build on sales gains
• For Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of comparable period in 2018

Sharing Services Global Corporation’s (OTCQB: SHRG) Elepreneurs subsidiary has employed an interactive, video-based platform from VERB Technology Inc. to help it continue its significant sales growth in the direct-selling market. The company’s Elepreneurs, or independent sales force, is currently using the VERB platform in the United States, with plans to launch the platform soon in Canada (http://ibn.fm/Myltq).

The business-focused, customer relationship management (CRM), sales-enablement, proprietary platform from VERB received hundreds of five-star reviews on the Apple App Store and Google Play Store in just the first few weeks of use. The new VERB sales and marketing app offers sampling and interactive video features that support Elepreneurs’ company objectives.

“As Elepreneurs continue their North American expansion efforts, we expect to see our per-user licensed products scale in-line with that growth,” Nick Hoggan, VERB’s chief revenue officer, stated in a news release. “Additionally, with support provided by our back-end integration and interactive video features, we can ensure that Elepreneurs has the proper infrastructure that has already helped so many other companies grow their digital capabilities.”

SHRG credits its growth to the success of Elepreneurs employing a Blue Ocean selling strategy in the direct-sales market (http://ibn.fm/up2Ln). For Q1 2019, the three months ending July 31, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018 (http://ibn.fm/Eu1kw). In a 10-K SEC filing, SHRG reported record sales of $85.9 million for its fiscal year ended April 30, 2019 (http://ibn.fm/S6xaA). This represents a nine-fold increase, or a $77.5 million jump from revenues of $8.4 million the prior year.

The Blue Ocean Strategy is an approach to selling that makes the competition irrelevant by operating in and creating an uncontested market space. Strategy execution calls for exceeding expectations. The strategy stems from the book Blue Ocean Strategy by W. Chan Kim and Renée Mauborgne. “Our Q1 revenues demonstrate that our Blue Ocean Strategy has taken root and continues to grow in the direct-selling marketplace,” added SHRG CEO John “JT” Thatch.

In addition, the company has announced global expansion plans, which it will continue to implement throughout 2019. “We continue at a record-breaking pace as our dedicated and highly talented Elepreneurs continue to execute on the mission to change the direct-selling industry with best-in-class products and services,” Thatch continued (http://ibn.fm/2NB9h).

The launch of SHRG’s proprietary line of health and wellness products in December 2017 through its Elepreneurs and Elevacity Global subsidiaries was a company milestone. The line consists of three sectors: anti-aging skin care, functional beverages, and natural supplements. All are based on the D.O.S.E. product formulation of four hormones designed to promote happiness and well-being (http://ibn.fm/MCnAG). SHRG has generated $129 million in cumulative sales since the product launch.

SHRG is a Plano, Texas-based diversified holdings company that owns, operates or controls a variety of companies engaged in direct selling through independent sales contractors. The company also offers services such as energy, technology and insurance.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at  http://ibn.fm/SHRG

• Predictive Oncology subsidiary TumorGenesis developing faster, less costly, and more accurate PDx cancer models that better mimic the patient’s tumor
• TumorGenesis revolutionary technology will provide pharmaceuticals with quicker and more effective drug development while significantly improving patient outcomes
• There’s an unmet need for a multi-omic approach (genome, transcriptome, epigenome, proteome, responseome, and microbiome), but such data is difficult to generate quickly.
• Predictive Oncology has access to historical data that competitors need at least five years to develop, which presents a multi-million-dollar market opportunity

The global cancer diagnostics market was valued at $144.4 billion in 2018 and is expected to grow at a 7.0% CAGR over the next six years on the back of increasing prevalence of oncologic cases, rapid technological advancement, and rising demand for effective screening tests. Within this broader cancer market, the Patient Derived Xenograft (PDx) segment, which involves a personalized approach to cancer treatment, was valued at $ 77.4 million in 2017 and is expected to grow at a CAGR of 16.7%, reaching $167.6 million by 2022. The driving forces behind this growth include the increasing demand for personalized medicine as well as public and private commitment to cancer research coupled with the growing R&D activities in the pharmaceutical industry.

TumorGenesis, a subsidiary of Predictive Oncology Inc. (NASDAQ: POAI), was established in 2018 to tap into this lucrative market with its unique way to capture and culture cancer cells and screen drug combinations for personalized cancer treatment. The parent company, Predictive Oncology, aims to deliver cutting-edge services for the oncology research and profiling market.

The problem with traditional cancer research is that it relies on the procedure whereby cancer cells need to be immortalized before they can be multiplied into colonies, which are then used in further research. Immortalization, however, renders all the cells identical, resulting in homogeneous cancer cell colonies, a characteristic that is far from true for the cancer cells found in human patients. What the scientific community now realizes is that cancer tissue comes as a mixture of rapidly mutating cell variants with unpredictable behavior, which means that traditional models are not sufficiently reliable.

However, there’s a paradigm shift occurring in cancer research as Patient Derived Xenografts (PDx) cancer models are developed. These are models where the cells from a patient’s tumor are taken, cultured, and then implanted into immunodeficient mice and rats – but the challenge is to keep the cells uncompromised during the process. TumorGenesis is part of this novel line of cutting-edge research as the company developed a proprietary technology that enables tumors to be grown in the lab in a medium that tricks the tumor cells into thinking they are still in the body.

TumorGenesis excels not only in identifying cancer cell lines but also in developing a medium necessary to grow cancer cell colonies in a way that will not compromise their integrity – a consideration critical to the success of every cancer research. This revolutionary technology is creating an unparalleled competitive advantage for the parent company POAI, as it allows for faster and more accurate identification of tumors and the development of patient-specific treatment options. The company expects this revolutionary product to hit the market by the end of the year.

What is unique with TumorGenesis’ state-of-the-art approach to cancer research is that the company has already developed 25 validated ovarian cancer cell types that mature into uncompromised tumor colonies not only in vitro but in rats and mice, too – a formidable accomplishment as 15 out of 25 cell lines represent around 90% of all ovarian cancers discovered so far, including those most virulent and deadly.

The company is also at the forefront of immunoncological research as it developed the proprietary technology called Ovarian Cancer Kit that uses the patient’s immune system to identify cancer cell types, inhibit their growth, and categorize their response to drug treatment. These developments are possible as the parent company POAI holds the world’s largest database of tumor drug response profiles and other multi-omic data, which they leverage to develop Artificial Intelligence-powered predictive models of therapy response. This enables more rapid target drug identification and significantly improves the drug approval rates, giving the company an unrivaled competitive edge.

POAI intends to make an impact in the precision medicine business with the goal of monetizing its assets within 18 months to reach a valuation comparable to its peers of $250 million. Unlike most competitors, the company has access to historical data on clinical outcomes and can generate value to pharmaceuticals much faster, while competitors must wait at least five years for the data. With a current valuation of only about $13 million, POAI is a compelling opportunity in the rapidly growing oncology outsourcing market, estimated to exceed $24 billion by 2026.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• SPRWF welcomes new senior vice president of commercial to executive team
• Joel Toguri to advance and oversee company’s provincial, retail sales operations across all brands
• New VP has two decades of experience spanning the cannabis, alcohol beverage, and apparel industries

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), a global diversified portfolio of cannabis companies, has announced the appointment of a new senior vice president of commercial (http://ibn.fm/2dtS0). With more than two decades of regulated industry expertise under his belt, including experience working in the cannabis space, Joel Toguri is well suited to further strengthening the SPRWF executive team. In his new role, Toguri will establish and oversee the company’s provincial and retail sales operations across all brands, including developing and driving forward-leading sales strategies, business development and retail-growth opportunities.

“Mr. Toguri’s impressive career spans the cannabis, beverage alcohol and apparel industries,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “He brings over 20 years of regulated industry knowledge and pertinent cannabis distribution expertise to Supreme Cannabis. It is a privilege to welcome a proven and skilled leader to our continuously improving team.

SPRWF’s premium wellness brand and multi-licensed processor and distributor Blissco recently launched its first product (http://ibn.fm/3Nub5) in a line of high-quality CBD oil products. This is one of many initiatives Toguri will be supporting, noted Dhaliwal.

“From the outset, Mr. Toguri will lead the launch of Blissco’s high-quality CBD oils to the Canadian wellness market and continue to build the 7ACRES brand and distribution to cement it as the leading premium flower brand nationally,” Dhaliwal continued. “The company’s talented sales team will benefit from Joel’s proven leadership abilities and strong industry network across Canada. As we grow our team, we believe our focused business and industry leading culture will continue to attract exceptional personnel like Mr. Toguri.”

The company noted that Toguri is uniquely equipped for the role, having already led sales at a large Ontario-based licensed producer in Canada, where he oversaw medical and recreational sales to patients and consumers. Before entering the cannabis industry, Toguri served as vice president of sales and operations at Southern Glazer’s of Canada, where he was responsible for establishing the company’s footprint across Canada and leading a national sales team of more than 90 people. During Toguri’s three-year tenure in that position, the company became one of the leading wine and spirits agents and brokers in Canada. Prior to his stint at Southern Glazer’s, Toguri held leadership roles at MolsonCoors and Beam Global Spirits & Wine.

Supreme Cannabis’ portfolio includes 7ACRES, its wholly owned subsidiary and multi-award-winning brand; Blissco, a wellness cannabis brand and a multilicensed processor and distributor based in British Columbia; Truverra Inc., a global medicinal cannabis brand and licensed cultivator; Cambium Plant Sciences, a plant genetics and cultivation IP company; Medigrow Lesotho, a cannabis oil producer located in Southern Africa; Supreme Heights, an investment platform focused on CBD brands in the UK and Europe; and a brand partnership and licensing deal with Khalifa Kush Enterprises Canada.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at  http://ibn.fm/SPRWF

• Lexaria Bioscience is a company that is passionate about establishing alternatives to inhalation for rapid-response drug substance delivery in order to eliminate the lung harm that smoking or vaping may cause
• Lexaria’s DehydraTECH platform has generated numerous patents with more pending as a way to provide quick substance delivery to the user’s bloodstream and better access through the blood-brain barrier
• Lexaria recently announced it had further improved DehydraTECH, as demonstrated in testing that showed early pilot-stage human trial participants began to note edible THC effects in under 10 minutes – more rapidly than the previous DehydraTECH formulation
• Prior technology testing has focused on animal subjects and non-psychoactive products

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is announcing further advances in its proprietary oral drug delivery platform DehydraTECH™, which is innovating edible consumption of nicotine and cannabis products as a quick-response alternative to inhalation.

Lexaria’s early pilot-stage human trials with tetrahydrocannabinol (THC) delivery show its newest formulation of DehydraTECH-enhanced edibles begin providing cannabinoid effectiveness in less than 10 minutes, which is about twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations, according to a company news release (http://ibn.fm/mwAS9).

Lexaria has been developing DehydraTECH solutions as alternatives to smoked or vaped drug delivery over the course of the past three years, establishing a means whereby edible consumption of certain substances can provide results at rates comparable to inhaled substances and faster than ingested substances in general.

In June, the company announced that a series of animal studies showed its DehydraTECH solution could improve on cannabidiol (CBD) delivery to the blood system by 811 percent and to brain tissue by 1,937 percent when compared with generic medium-chain triglyceride (MCT) formulations.

The latest announcement marks a new milestone in that the studies involved humans instead of animals and utilized THC instead of CBD, demonstrating further potential applications of DehydraTECH technology.

Speed of onset in the use of various drug products is regarded as a key metric of the products’ potential value, particularly where pain-relief and the relief of other physical torments are concerned. For example, nicotine is recognized as a highly addictive substance that can provoke then alleviate physical withdrawal symptoms or cravings, while certain cannabis extracts have been promoted in recent years as significant remedies for pain and muscle spasms or seizure disorders.

Inhalation has traditionally shown the greatest benefit in terms of rapid-response drug delivery benefits, but Lexaria has been passionate about delivering alternatives because of the harm substance inhalation can do to users’ lungs, as demonstrated by the history of smoking tobacco products and recent concerns about deaths and illnesses linked to vaping cannabis or nicotine products, which in turn have led health insurers to penalize customers who smoke or vape products (http://ibn.fm/x5rDh).

Because of DehydraTECH’s rapid-response capabilities, Lexaria’s technology virtually eliminates a key reason people might risk sustained injury to their lungs in using tobacco and cannabis products. Lexaria’s tech works as a complimentary product with other companies’ research and development on cannabinoids, providing Lexaria a niche as a potential collaborative team member rather than a competitor as other industry developments occur.

Lexaria’s position is further strengthened by its worldwide patents and pending patents for oral or ingestible non-psychoactive cannabinoids – it has been awarded 16 patents in the United States and Australia and is awaiting completion of the process for 60 additional patents in other countries (http://ibn.fm/W46qw).

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP